Genomics in Multiple Myeloma: From Conventional Cytogenetics to Novel Whole-Genome Sequencing Approaches

Francesca Cottini, Kenneth C. Anderson, Giovanni Tonon

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Multiple myeloma (MM) is a clonal proliferation of abnormal plasma cells in the bone marrow (BM), associated with a monoclonal protein and end-organ damage. MM originates from a pre-malignant condition, called monoclonal gammopathy of undetermined significance (MGUS) and can progress to an extramedullary disease, termed plasma cell leukemia (PCL), which invades the bloodstream. MM cells manifest a wide spectrum of genomic abnormalities, creating a strong intertumoral heterogeneity. Historically, MM patients have been divided into two subgroups: hyperdiploid cases (with >46 chromosomes) and non-hyperdiploid cases. However, the introduction of novel technologies such as fluorescence in situ hybridization (FISH), array comparative genomic hybridization (aCGH) and sequencing techniques is helping to unveil the complexity of MM genomes. In particular, MM cells present: recurrent translocations which deregulate known oncogenes, such as CCND1, FGFR3-MMSET, c-MAF and MYC, numerous copy number variations (CNVs) including deletion of chromosome 13, deletion of chromosome 17p13, and amplification of chromosome 1q21; and various somatic mutations in genes involved in cancer proliferation (. RAS, BRAF, FGFR3), protein homeostasis and RNA processing (. FAM46C, DIS3, XBP1 and LRRK2); NF κB signaling; histone methylation; and tumor suppression (. TP53). This chapter will summarize our current knowledge of the MM genomic field, focusing on the different types of abnormalities and their relationship with the phases of disease.

Original languageEnglish
Title of host publicationCancer Genomics: From Bench to Personalized Medicine
PublisherElsevier Inc.
Pages301-319
Number of pages19
ISBN (Print)9780123969675
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Chromosomes
Genomics
Multiple Myeloma
Cytogenetics
Genes
Genome
Receptor, Fibroblast Growth Factor, Type 3
Plasmas
Methylation
Histones
Amplification
Tumors
Plasma Cell Leukemia
Bone
Monoclonal Gammopathy of Undetermined Significance
Fluorescence
Chromosomes, Human, Pair 13
Chromosome Deletion
RNA
Polyploidy

Keywords

  • Copy number variations
  • Monoclonal gammopathy of undetermined significance
  • Multiple myeloma
  • Mutations
  • NF κB
  • Plasma cells
  • Proteasome
  • Protein homeostasis
  • Translocations

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Cottini, F., Anderson, K. C., & Tonon, G. (2013). Genomics in Multiple Myeloma: From Conventional Cytogenetics to Novel Whole-Genome Sequencing Approaches. In Cancer Genomics: From Bench to Personalized Medicine (pp. 301-319). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-396967-5.00018-9

Genomics in Multiple Myeloma : From Conventional Cytogenetics to Novel Whole-Genome Sequencing Approaches. / Cottini, Francesca; Anderson, Kenneth C.; Tonon, Giovanni.

Cancer Genomics: From Bench to Personalized Medicine. Elsevier Inc., 2013. p. 301-319.

Research output: Chapter in Book/Report/Conference proceedingChapter

Cottini, F, Anderson, KC & Tonon, G 2013, Genomics in Multiple Myeloma: From Conventional Cytogenetics to Novel Whole-Genome Sequencing Approaches. in Cancer Genomics: From Bench to Personalized Medicine. Elsevier Inc., pp. 301-319. https://doi.org/10.1016/B978-0-12-396967-5.00018-9
Cottini F, Anderson KC, Tonon G. Genomics in Multiple Myeloma: From Conventional Cytogenetics to Novel Whole-Genome Sequencing Approaches. In Cancer Genomics: From Bench to Personalized Medicine. Elsevier Inc. 2013. p. 301-319 https://doi.org/10.1016/B978-0-12-396967-5.00018-9
Cottini, Francesca ; Anderson, Kenneth C. ; Tonon, Giovanni. / Genomics in Multiple Myeloma : From Conventional Cytogenetics to Novel Whole-Genome Sequencing Approaches. Cancer Genomics: From Bench to Personalized Medicine. Elsevier Inc., 2013. pp. 301-319
@inbook{6366ade21c8646029d6f0c2fecfa9a66,
title = "Genomics in Multiple Myeloma: From Conventional Cytogenetics to Novel Whole-Genome Sequencing Approaches",
abstract = "Multiple myeloma (MM) is a clonal proliferation of abnormal plasma cells in the bone marrow (BM), associated with a monoclonal protein and end-organ damage. MM originates from a pre-malignant condition, called monoclonal gammopathy of undetermined significance (MGUS) and can progress to an extramedullary disease, termed plasma cell leukemia (PCL), which invades the bloodstream. MM cells manifest a wide spectrum of genomic abnormalities, creating a strong intertumoral heterogeneity. Historically, MM patients have been divided into two subgroups: hyperdiploid cases (with >46 chromosomes) and non-hyperdiploid cases. However, the introduction of novel technologies such as fluorescence in situ hybridization (FISH), array comparative genomic hybridization (aCGH) and sequencing techniques is helping to unveil the complexity of MM genomes. In particular, MM cells present: recurrent translocations which deregulate known oncogenes, such as CCND1, FGFR3-MMSET, c-MAF and MYC, numerous copy number variations (CNVs) including deletion of chromosome 13, deletion of chromosome 17p13, and amplification of chromosome 1q21; and various somatic mutations in genes involved in cancer proliferation (. RAS, BRAF, FGFR3), protein homeostasis and RNA processing (. FAM46C, DIS3, XBP1 and LRRK2); NF κB signaling; histone methylation; and tumor suppression (. TP53). This chapter will summarize our current knowledge of the MM genomic field, focusing on the different types of abnormalities and their relationship with the phases of disease.",
keywords = "Copy number variations, Monoclonal gammopathy of undetermined significance, Multiple myeloma, Mutations, NF κB, Plasma cells, Proteasome, Protein homeostasis, Translocations",
author = "Francesca Cottini and Anderson, {Kenneth C.} and Giovanni Tonon",
year = "2013",
month = "12",
doi = "10.1016/B978-0-12-396967-5.00018-9",
language = "English",
isbn = "9780123969675",
pages = "301--319",
booktitle = "Cancer Genomics: From Bench to Personalized Medicine",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Genomics in Multiple Myeloma

T2 - From Conventional Cytogenetics to Novel Whole-Genome Sequencing Approaches

AU - Cottini, Francesca

AU - Anderson, Kenneth C.

AU - Tonon, Giovanni

PY - 2013/12

Y1 - 2013/12

N2 - Multiple myeloma (MM) is a clonal proliferation of abnormal plasma cells in the bone marrow (BM), associated with a monoclonal protein and end-organ damage. MM originates from a pre-malignant condition, called monoclonal gammopathy of undetermined significance (MGUS) and can progress to an extramedullary disease, termed plasma cell leukemia (PCL), which invades the bloodstream. MM cells manifest a wide spectrum of genomic abnormalities, creating a strong intertumoral heterogeneity. Historically, MM patients have been divided into two subgroups: hyperdiploid cases (with >46 chromosomes) and non-hyperdiploid cases. However, the introduction of novel technologies such as fluorescence in situ hybridization (FISH), array comparative genomic hybridization (aCGH) and sequencing techniques is helping to unveil the complexity of MM genomes. In particular, MM cells present: recurrent translocations which deregulate known oncogenes, such as CCND1, FGFR3-MMSET, c-MAF and MYC, numerous copy number variations (CNVs) including deletion of chromosome 13, deletion of chromosome 17p13, and amplification of chromosome 1q21; and various somatic mutations in genes involved in cancer proliferation (. RAS, BRAF, FGFR3), protein homeostasis and RNA processing (. FAM46C, DIS3, XBP1 and LRRK2); NF κB signaling; histone methylation; and tumor suppression (. TP53). This chapter will summarize our current knowledge of the MM genomic field, focusing on the different types of abnormalities and their relationship with the phases of disease.

AB - Multiple myeloma (MM) is a clonal proliferation of abnormal plasma cells in the bone marrow (BM), associated with a monoclonal protein and end-organ damage. MM originates from a pre-malignant condition, called monoclonal gammopathy of undetermined significance (MGUS) and can progress to an extramedullary disease, termed plasma cell leukemia (PCL), which invades the bloodstream. MM cells manifest a wide spectrum of genomic abnormalities, creating a strong intertumoral heterogeneity. Historically, MM patients have been divided into two subgroups: hyperdiploid cases (with >46 chromosomes) and non-hyperdiploid cases. However, the introduction of novel technologies such as fluorescence in situ hybridization (FISH), array comparative genomic hybridization (aCGH) and sequencing techniques is helping to unveil the complexity of MM genomes. In particular, MM cells present: recurrent translocations which deregulate known oncogenes, such as CCND1, FGFR3-MMSET, c-MAF and MYC, numerous copy number variations (CNVs) including deletion of chromosome 13, deletion of chromosome 17p13, and amplification of chromosome 1q21; and various somatic mutations in genes involved in cancer proliferation (. RAS, BRAF, FGFR3), protein homeostasis and RNA processing (. FAM46C, DIS3, XBP1 and LRRK2); NF κB signaling; histone methylation; and tumor suppression (. TP53). This chapter will summarize our current knowledge of the MM genomic field, focusing on the different types of abnormalities and their relationship with the phases of disease.

KW - Copy number variations

KW - Monoclonal gammopathy of undetermined significance

KW - Multiple myeloma

KW - Mutations

KW - NF κB

KW - Plasma cells

KW - Proteasome

KW - Protein homeostasis

KW - Translocations

UR - http://www.scopus.com/inward/record.url?scp=84902393314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902393314&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-396967-5.00018-9

DO - 10.1016/B978-0-12-396967-5.00018-9

M3 - Chapter

AN - SCOPUS:84902393314

SN - 9780123969675

SP - 301

EP - 319

BT - Cancer Genomics: From Bench to Personalized Medicine

PB - Elsevier Inc.

ER -